FDA promises swift review of GSK's blockbuster HIV hopeful

Based on the big promise of GlaxoSmithKline's ($GSK) dolutegravir, the FDA has granted the potential HIV drug a priority review of 6 months rather than the standard 10 months. The agency gave an Aug. 17 action date for its review of the drug. London-based GSK controls a majority stake in the product, which is owned by its ViiV Healthcare joint venture with Pfizer ($PFE). Analysts believe that dolutegravir could be a multibillion-dollar seller which competes well with HIV drug powerhouse Gilead Sciences' ($GILD) meds. Article

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.